Berinert (C1 esterase inhibitor (human) IV) / CSL Behring  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
NCT02936479: C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

Checkmark In refractory AMR
May 2016 - May 2016: In refractory AMR
Completed
2
1
US
C1-INH (Berinert)
NYU Langone Health, CSL Behring
Antibody Mediated Rejection of Kidney Transplant
10/18
10/18
2020-002225-29: Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections. Evaluation des effets des antagonistes de la bradykinine sur les manifestations pulmonaires des infections à COVID-19.

Not yet recruiting
2
45
Europe
Concentrate and solvent for solution for injection/infusion, Solution for injection in pre-filled syringe, BERINERT, FIRAZYR
Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche, Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche
COVID positive patients with respiratory impairment Patients COVID + avec atteinte respiratoire, COVID positive patients with respiratory impairment Patients COVID + avec atteinte respiratoire, Diseases [C] - Virus Diseases [C02]
 
 
NCT01576523: A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Completed
1/2
18
Europe, US
C1-esterase inhibitor - single intravenous dose, C1-esterase inhibitor - subcutaneous low dose, C1-esterase inhibitor - subcutaneous medium dose, C1-esterase inhibitor - subcutaneous high dose
CSL Behring, Parexel
Hereditary Angioedema Types I and II
12/12
12/12
NCT01134510: Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Completed
1/2
20
US
C1 Esterase Inhibitor, Berinert, Placebos
Stanley Jordan, MD, CSL Behring
Kidney Transplantation
11/13
11/13
C1INHDGF, NCT02134314: C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

Completed
1/2
70
US
C1 Esterase Inhibitor, Berinert (C1INH), Placebo, Normal Saline (0.9%NaCl)
Cedars-Sinai Medical Center
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
03/17
03/17
NCT04696146: Berinert (C1INH) vs Placebo for DGF/IRI

Active, not recruiting
1/2
45
US
Berinert, C1 Esterase Inhibitor (C1INH), Placebo, Normal Saline
Cedars-Sinai Medical Center, OneLegacy Foundation
End Stage Renal Disease, Chronic Kidney Diseases
07/22
03/24

Download Options